CytoDyn Inc (OTCMKTS:CYDY) Stock Attempts To Bounce Back: Will it Sustain?

August 16, 2021

The presence of activist investors in a company can often lead to a fair degree of uncertainty for investors but last week the CytoDyn Inc (OTCMKTS:CYDY) stock actually performed strongly. There was no news about the biopharmaceutical company last week but the stock performed strongly. On Friday, it jumped by 5% and ended the week with gains of as much as 12.50%. In this situation, it might be a good…

Read More >>

CytoDyn Inc. (OTCMKTS:CYDY) Stock Continues to Struggle At Lower Levels: Now What?

August 11, 2021

CytoDyn Inc. (OTCMKTS:CYDY) is down 6% in a week after announcing approval from Brazilian regulatory agency ANVISA for its previously submitted clinical study protocol to start patient recruitment in the CD17 study for severe coronavirus patients. The company will, in collaboration, conduct the trial with Academic Research Organisation Albert Einstein Israelite Hospital. The study will produce requisite data needed by ANVISA to consider leronlimab’s availability to patients with severe CPVID-19…

Read More >>

CytoDyn Inc (OTCMKTS:CYDY) Stock Slips To A New Low: Should You Panic?

August 5, 2021

Late-stage biotechnology firm, CytoDyn Inc (OTCMKTS:CYDY) on August 3, 2021, announced that director nominations done by an activist group led by Bruce Patterson and Paul Rosenbaum were invalid. The Group attempted on nominating five director candidates for taking over control of the firm’s six-member Board of Directors. CytoDyn’s bylaws have a standard “advance notice bylaw” for protecting shareholders, requiring disclosures through shareholder nomination as well as nominees for providing all…

Read More >>

CytoDyn Inc (OTCMKTS:CYDY) Stock Resumes Selling Pressure: A Good Buy Now?

August 3, 2021

Late stage biotech firm CytoDyn Inc (OTCMKTS:CYDY) was in the middle of a heavy selloff yesterday in the markets and saw its stock slump by as much as 9%. The selloff in the stock was possibly triggered by an announcement from CytoDyn with regards to the director nominations that had been submitted by an activist investor group. The company announced that the nominations from the activist investors group, headed by…

Read More >>

CytoDyn (OTCMKTS:CYDY) Stock Sees High Volatility: What’s The Buzz?

August 2, 2021

Late-stage biotechnology company developing innovative treatments for multiple therapeutic indications, CytoDyn (OTCMKTS:CYDY), on August 2, 2021 announced that director nominations done by activist group led by Bruce Patterson and Paul Rosenbaum were invalid. The Rosenbaum/Patterson Group made efforts for nominating five director candidates for taking control of the firm’s Board of Directors.  The company’s bylaws include standard “advance notice bylaw” for shareholder protection, requiring some disclosures by nominating shareholders for…

Read More >>

CytoDyn Inc. (OTCMKTS: CYDY) Releases Leronlimab Results of COVID-19 Long-Haulers Study

July 6, 2021

CytoDyn Inc. (OTCMKTS: CYDY) has announced the initial result following the unblinding of the data from the ongoing long COVID clinical trial.  Leronlimba alleviated COVID-19 symptoms.  The COVID-19 long-haulers study sought to assess the efficacy and safety of leronlimab delivered subcutaneously weekly to subjects showing prolonged COVID-19 symptoms. The study’s primary endpoint was a change from baseline in COVID-19 related symptom severity through the 56th day. Progression of COVID-19-related symptoms…

Read More >>